Articles by Elizabeth Swanson, MD

Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 3
ByLauren Buchanan, MA, Managing Editor,Linda Stein Gold, MD,Michael Cameron, MD, FAAD,James Q. Del Rosso, DO,Brad Glick, DO, MPH,Elizabeth Swanson, MD A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.

Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 2
ByLauren Buchanan, MA, Managing Editor,Linda Stein Gold, MD,Michael Cameron, MD, FAAD,James Q. Del Rosso, DO,Brad Glick, DO, MPH,Elizabeth Swanson, MD A 5-expert panel continues their conversation on atopic dermatitis, exploring beyond steroids and addressing unmet needs.

Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 1
ByLauren Buchanan, MA, Managing Editor,Linda Stein Gold, MD,Michael Cameron, MD, FAAD,James Q. Del Rosso, DO,Brad Glick, DO, MPH,Elizabeth Swanson, MD A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

Patient Case #3: 32-Year-Old Male With AD
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Expert dermatologists review a final case about a 32-year-old male with AD, highlighting systemic therapy as first-line treatment.

Counseling AD Patients on Injection Concerns
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Elizabeth Swanson, MD, shares pearls on how to communicate with AD patients who are uncertain about treatment through self-administered injection.

Guidelines and Recommendations for Therapies in AD
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Experts in dermatology review recommendations for systemic therapies and JAK inhibitors in the management of AD and other factors that guide treatment selection.

Patient Case #2: Adolescent Male With AD
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, discuss their initial impressions of an adolescent patient with AD, focusing on systemic therapy.

Patient Case #1: AD Treatment Options
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, highlight treatment options for a specific patient with AD, focusing on dupilumab.

Treatment of AD in Clinical Practice
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Experts in dermatology review clinical trials for AD treatment and how this data translates into their own practices.

Use of Dupilumab in AD
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Expert dermatologists review the use of dupilumab for the treatment of AD, focusing on the once-monthly shot as a factor in selection.

Patient Case #1: AD Treatment Approaches
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Elizabeth Swanson, MD, and Brad Glick, DO, MPH, FAOCD, share treatment approaches for pediatric patients with AD.

Patient Case #1: 6-Year-Old Male Patient With Moderate AD
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Expert dermatologists present and share initial impressions of a patient case for a 6-year-old male with AD, highlighting the impact of sleep deprivation.

Switching Treatment in AD
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, review factors that lead to switching therapies in AD, focusing on monotherapies vs combination therapy.

Time to Treatment Response in AD Treatment Selection
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Experts in dermatology comment on how often quickness of response to therapy determines treatment selection for teenaged patients with AD.

Treatment Selection for AD
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Expert dermatologists discuss treatment selection for short-term rescue vs long-term maintenance therapy.

Use of Systemic vs Topical Treatment of AD
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Andrew Blauvelt, MD, MBA, reviews systemic vs topical treatment of AD, discussion patient preferences as a factor for treatment selection.

Treatment Landscape for Atopic Dermatitis (AD)
ByJonathan I Silverberg, MD, PhD, MPH,Brad Glick, DO, MPH,Andrew Blauvelt, MD, MBA,Elizabeth Swanson, MD Experts in dermatology discuss the rapidly expanding treatment landscape of atopic dermatitis and how these new treatment options have changed the management of AD.

Take-Home Points
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, provide take-home messages for dermatologists treating pediatric patients with atopic dermatitis.

Case 3 Continued: How to Have Conversation About Risk of Biologics and Length of Therapy
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Atopic dermatitis specialists discuss how to have a conversation with parents about risks of biologics and how to answer questions about length of therapy.

Case 3 Continued: Impressions
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Expert pediatric dermatologists provide impressions on the case of a 12-year-old girl with atopic dermatitis.

Case 3: 12-Year-Old-Female With Atopic Dermatitis
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Joshua Zeichner, MD, reviews the case of a 12-year-old girl with atopic dermatitis.

Case 2 Continued: Importance of Combination Therapy and Shared Decision Making
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Expert pediatric dermatologists discuss the importance of combination therapy and shared decision-making when treating pediatric patients with atopic dermatitis.

Case 2 Continued: Barriers to Treatment Adherence
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Brittany Craiglow, MD, and Joshua Zeichner, MD, discuss treatment adherence in pediatric patients with atopic dermatitis.

Case 2 Continued: Impressions and Recommendations
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Vikash Oza, MD, provides clinical insight for Case 2, a 7-year-old female patient with atopic dermatitis.

Case 2 Continued: Addressing Injectable Medications in Children
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; and Vikash Oza, MD, address techniques for injectables when treating pediatric patients with atopic dermatitis.

Case 2: 7-Year-Old Female With Atopic Dermatitis
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Dr Joshua Zeichner reviews the case of a 7-year-old female patient with atopic dermatitis.

Case 1 Continued: Treatments Beyond Topical Agents and the Use of Dupixent
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, discuss treatments beyond topical agents and the use of dupilumab in pediatric patients with atopic dermatitis.

Case 1 Continued: Clinical Impressions
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Expert pediatric dermatologists Drs Elizabeth Swanson, Joshua Zeichner, and Raj Chovatiya share impressions from patient case No. 1.

Case 1: 2-Year-Old Male With Atopic Dermatitis
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Dr Joshua Zeichner reviews the case of a 2-year-old patient with atopic dermatitis.

Pharmacological Options for the Treatment of Pediatric Atopic Dermatitis
ByJoshua Zeichner, MD,Brittany Craiglow, MD,Elizabeth Swanson, MD,Vikash Oza, MD,Raj Chovatiya, MD, PhD, MSCI Experts treating pediatric atopic dermatitis discuss the pharmacological options for the treatment of pediatric atopic dermatitis.